![Robert Gould](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert Gould
Direktor/Vorstandsmitglied bei
FULCRUM THERAPEUTICS, INC.
Vermögen: 3 Mio $ am 31.05.2026
Profil
Robert J.
Gould is currently Chairman at HemoShear Therapeutics, Inc. since 2022.
Current roles also include Director positions at Spring Arbor University, Turnstone Biologics, Inc., Fulcrum Therapeutics, Inc. since 2023, Rubedo Life Sciences, Inc., and Faeth Therapeutics, Inc. Former roles include Secretary & Director at Epizyme, Inc. from 2015 to 2016, Director at The Broad Institute, Inc. from 2006 to 2010, Independent Director at Turnstone Biologics Corp.
from 2019 to 2025, Vice President-Basic Research at Merck Research Laboratories Massachusetts LLC, and Operating Partner at Khosla Ventures LLC.
Education includes an undergraduate degree from Spring Arbor University in 1976 and a doctorate from the University of Iowa.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2026 | 454.864 ( 0,68 % ) | 3 Mio $ | 31.05.2026 |
Aktive Positionen von Robert Gould
| Unternehmen | Position | Beginn |
|---|---|---|
| FULCRUM THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 19.07.2016 |
HemoShear Therapeutics, Inc.
 HemoShear Therapeutics, Inc. Medical/Nursing ServicesHealth Services Creates human relevant systems that replicate the biology of organ systems and diseases | Vorsitzender | 25.08.2022 |
Turnstone Biologics, Inc.
 Turnstone Biologics, Inc. BiotechnologyHealth Technology Develops bio-therapeutics for the treatment of cancer | Direktor/Vorstandsmitglied | - |
Spring Arbor University
 Spring Arbor University Other Consumer ServicesConsumer Services Functions as a College/University | Direktor/Vorstandsmitglied | - |
Rubedo Life Sciences, Inc.
 Rubedo Life Sciences, Inc. BiotechnologyHealth Technology Discovers and develops therapeutics & medicines that helps to stay young | Direktor/Vorstandsmitglied | - |
Faeth Therapeutics, Inc.
 Faeth Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops precision nutrition cancer treatment solutions which uses metabolism to starve cancer cells | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Robert Gould
| Unternehmen | Position | Ende |
|---|---|---|
| TURNSTONE BIOLOGICS CORP. | Direktor/Vorstandsmitglied | 11.08.2025 |
| EPIZYME, INC. | Vorstandsvorsitzender | 10.09.2015 |
The Broad Institute, Inc.
 The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases | Direktor/Vorstandsmitglied | - |
| ░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | - |
| ░░░░░ ░░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Robert Gould
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
44
Beziehungen ersten Grades
12
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 12 |
|---|---|
HemoShear Therapeutics, Inc.
HemoShear Therapeutics, Inc. Medical/Nursing ServicesHealth Services Creates human relevant systems that replicate the biology of organ systems and diseases | Health Services |
Spring Arbor University
Spring Arbor University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Iowa
 University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Khosla Ventures LLC
 Khosla Ventures LLC Investment ManagersFinance Khosla Ventures invests in companies located in the United States with transaction size that exceed USD 10 million. The firm targets companies operating across a broad range of sectors and industries. It participates in seed, early and later stage capital requirements with an revenue ranging from USD 50 to 150 million. | Finance |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Health Technology |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Develops therapeutics for the treatment of patients with genetically defined cancers | Health Technology |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases | Health Technology |
Turnstone Biologics, Inc.
Turnstone Biologics, Inc. BiotechnologyHealth Technology Develops bio-therapeutics for the treatment of cancer | Health Technology |
Fulcrum Therapeutics, Inc.
 Fulcrum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines for patients by transforming gene regulation in disease | Health Technology |
Turnstone Biologics Corp.
 Turnstone Biologics Corp. BiotechnologyHealth Technology Develops and sells medicines to treat and cure solid tumors | Health Technology |
Rubedo Life Sciences, Inc.
Rubedo Life Sciences, Inc. BiotechnologyHealth Technology Discovers and develops therapeutics & medicines that helps to stay young | Health Technology |
Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops precision nutrition cancer treatment solutions which uses metabolism to starve cancer cells | Health Technology |
